Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Spain,Slovakia,Canada,Germany,France,Russian Federation,Belgium,Mexico,Poland,Australia
nct
MAJ Il y a 5 ans
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death
The Primary objective was to assess the efficacy of Celivarone for the prevention of Implantable Cardioverter Defibrillator (ICD) interventions or death. Secondary objectives were: - To assess the tolerability and safety of the different dose regimens of Celivarone in the selected population. - To document Celivarone plasma levels during the study.
Pays
Argentina
,
Australia
,
Belgium
,
Canada
,
Chile
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Japan
,
Mexico
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Turkey
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Pays
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Mexico
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1